|Printable version||E-mail this to a friend|
How big data can be used for the development and regulation of medicines
EMA workshop broadcast live on 14-15 November
The European Medicines Agency (EMA) is organising a workshop on 14-15 November 2016 to identify opportunities for big data in medicines development and regulation, and to address the challenges of their exploitation. You can follow a live broadcast of the workshop by clicking on the ‘multimedia’ tab on the event page.
Big data is a term which describes the collection of extremely large sets of information which require specialised computational tools to enable their analysis and exploitation. These vast volumes of data have the capability to significantly contribute to the way the benefit-risk of medicines is assessed over the entire lifecycle. A subset of big data is real world evidence, which encompasses the use of sources such as electronic health records, registries, hospital records and health insurance data. Already used to support pharmacovigilance activities, real world evidence has the potential to support product development and the assessment of performance of a medicine on the market.
While creating huge opportunities, there are also significant challenges in the exploitation of these data. For example there is a need to establish appropriate access to the data, to understand the strengths and limitations of the data and to apply new analytical methods to integrate and analyse heterogeneous datasets in order to generate conclusions which contribute to regulatory decision making. Importantly, compliance with data protection legislation ensuring robust mechanisms to protect patient confidentiality is critical for securing patient trust.
The workshop will bring together a wide range of individuals from the healthcare environment and technology companies, who can inform on the advances being made in the field of big data and the opportunities for its application in medicine regulation. This landscaping exercise will help regulators to determine the best approaches to using big data for the development, authorisation and post-marketing surveillance of medicines.
More details on this workshop’s sessions and speakers are provided in the agenda for the meeting.
Individuals interested in tweeting on this event are invited to use the hashtag #bigdata4medicines.
- Identifying opportunities for ‘big data’ in medicines development and regulatory science (14-15/11/2016)
- Agenda - Identifying opportunities for 'big data' in medicines development and regulatory science (08/11/2016)
Latest News from
Call for experts in anonymisation of clinical data23/03/2017 16:05:00
The EMA has launched a call for applications to join a technical anonymisation group (TAG) that will help the Agency to further develop best practices for the anonymisation of clinical reports. The goal is to set up a multidisciplinary team with a broad range of expertise.
Health systems: more integration to boost cooperation and reduce gaps in the EU23/03/2017 15:20:00
In its opinion adopted during the plenary session, CoR agrees on the need to improve the integration, cooperation and performance of health systems in the Union. The current health systems in the EU are affected by population ageing, costs of innovative medicine and new technologies, chronic diseases and inequalities in healthcare access.
First anniversary of PRIME – experience so far23/03/2017 15:05:00
The European Medicines Agency (EMA) is organising a meeting with its stakeholders to review the experience gained with its PRIME (PRIority Medicines) scheme one year after it was launched. Registration opens for stakeholder meeting on 19 May 2017.
Smart specialisation strategies: Stronger focus on synergies and interregional cooperation23/03/2017 14:20:00
The regulatory framework around smart specialisation strategies (RIS3) needs to be reformed to increase synergies between the European Structural & Investment Funds and regional innovation & development policies.